Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 14/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067969 | 0.84 | PDE4B (0.35) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL2066471 | 0.81 | PDE4A (0.40) | CA1CA2CA9MAPK1CA12 | |
| SCHEMBL2068153 | 0.81 | PDE4A (0.36) | CA1CA2CA9MAPK1CA12 | |
| SCHEMBL2066630 | 0.81 | CA1 (0.36) | CA1CA2CA9MAPK1CA12 | |
| SCHEMBL2065529 | 0.77 | PDE4A (0.43) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL2065638 | 0.77 | PDE4A (0.37) | CA1CA2CA9MAPK1CA12 | |
| SCHEMBL2066954 | 0.77 | PDE4A (0.40) | CA1CA2CA9MAPK1CA12 | |
| SCHEMBL2066052 | 0.77 | PDE4A (0.33) | CA1CA2CA9MAPK1CA12 | |
| SCHEMBL2066982 | 0.76 | PDE4A (0.39) | CA1CA2CA9MAPK1CA12 | |
| SCHEMBL2065708 | 0.75 | PDE4A (0.39) | CA1CA2CA9MAPK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148524-B2 | Process for producing sulfonyl chloride compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-1932846-B1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2010-10-27 | — | — | EP | disclosed |
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1932846-A1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SALL4, CLCN2, CLIC1 | CA1 1402/4885CA2 176/4885CA9 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.